Ann: EFFICACY IN TRANSPLANT REJECTION , page-14

Lipofectamine 2000 is the delivery technology and does not point to the rnai component unfortunately. If BLT had not have released the ASX announcement pointing out their involvement anyone could have been excused for thinking this was the main alternate rnai technology in play here.

Technology aside, all these non-core programs are a distraction right now. In reality we probably have about six months to go before we need to make arrangements to raise capital again. IMO we need to focus all of our attention on where we can get some traction. Right now our best chance is in helping Tacere to get a new sponsor. Failing that, selling a share in Nervana or Tribetarna is our best option. No other programs seem to be worth pursuing until we can get our funding sorted out.

I have to say that I am not too keen on the idea of putting my hand in my pocket just to maintain my existing shareholding so I would really like all the stops pulled out to get one of these deals done and forget the rest of the programs for the time being.